← Media

Quetiapine (Seroquel), olanzapine, and similar antipsychotics are sometimes used off-label for sleep. For routine insomnia, that is usually a poor risk-benefit tradeoff.

Why we avoid routine use

These medications can sedate, but sedation is not the same as restoring healthy sleep architecture. They also carry meaningful short- and long-term adverse effects.

Major risks

• Weight gain and metabolic changes
• Next-day sedation and cognitive slowing
• Movement side effects, including tardive syndromes
• Cardiometabolic risk, including diabetes and lipid abnormalities

When they might be considered

There are limited situations where they may be used, such as when an antipsychotic is already indicated for a psychiatric disorder or in select complex cases under close supervision. Using them only as a sleep aid is generally not recommended when safer options exist.

Better alternatives

CBT-I is first-line care for chronic insomnia. If medication is needed, options such as low-dose doxepin, DORAs (for example suvorexant or lemborexant), melatonin-receptor agonists, or cautious short-term hypnotic use may be considered based on individual risk profile.

Bottom line

• Routine neuroleptic use for insomnia is usually not justified by risk-benefit balance.
• Sedation alone is not a sufficient treatment goal.
• Use CBT-I and lower-risk sleep treatments whenever possible.

If you are currently taking a neuroleptic for sleep, do not stop abruptly. Discuss a supervised taper and transition plan with your clinician.

Educational content only; this is not personalized medical advice. If you have urgent symptoms, seek emergency care.